Tec Laboratories Taking Action on MRSA Concerns in FDA Warning

OTC pharmaceutical drug product manufacturer Tec Labs planning to work with agency to address issues related to StaphAseptic MRSA prevention claims

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Albany, OR (PRWEB) April 21, 2011

Tec Laboratories, makers of StaphAseptic® First Aid Antiseptic and Pain Relieving Gel – not a hand sanitizer – announced today it plans to work with the Food and Drug Administration to address the issues raised in a warning letter the company received this week from the government agency.

A registered manufacturer of over-the-counter (OTC) pharmaceutical drug products, Tec Laboratories has remained in good standing with the FDA for 30 years ensuring the products they manufacture and market meet the regulations appropriate for their category. Acting in complete agreement that MRSA prevention claims should be clear, accurate and proven based on established regulations, the company will take steps necessary to meet the agency’s primary concern for public health and safety.

“Based on our long history of working with the FDA, I am confident we can resolve this issue in a positive manner,” said Steve Smith, CEO of Tec Laboratories.

The FDA has provided Tec Laboratories with 15 working days from April 18 to respond to the letter.

About Tec Laboratories
Tec Laboratories, Inc., is an OTC pharmaceutical manufacturer headquartered in Albany, Oregon, that specializes in innovative topical products. The company was founded by Dr. Robert Smith in 1977.

###


Contact